PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
22450587-10	2012	We had previously experienced successful treatment with ABVD chemotherapy for interdigitating dendritic cell sarcoma after ineffective CHOP chemotherapy.	ABVD protocol	56-60	DNA damage inducible transcript 3	Homo sapiens	135-139
24686920-11	2021	CONCLUSION: visual assessment of early interim 18F-FDG-PET/CT after 2 cycles of ABVD in PHL showed a very significant role in prediction ofTAS and DFS.	ABVD protocol	80-84	BCR activator of RhoGEF and GTPase	Homo sapiens	88-91
24121121-6	2013	In the exploratory subset analysis including HD10 eligible patients who achieved complete response (CR) or unconfirmed complete response (CRu) after two cycles of ABVD, 8-year PFS was 87% (HD10) versus 95% (HD.6) (HR 2.8; 95% CI 0.64-12.5) and overall survival 96% versus 100%.	ABVD protocol	163-167	histone deacetylase 10	Homo sapiens	45-49
22547578-0	2012	Expression of COX-2 on Reed-Sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD.	ABVD protocol	125-129	prostaglandin-endoperoxide synthase 2	Homo sapiens	14-19
22296221-6	2012	METHODS: Retrospective analysis of the incidence of febrile neutropenia and treatment delay in a variety of different G-CSF schedules used as secondary prophylaxis in patients receiving ABVD.	ABVD protocol	186-190	colony stimulating factor 3	Homo sapiens	118-123
21762523-3	2011	Here, we studied the association between MDR1 C3435T polymorphism and susceptibility to Hodgkin lymphoma (HL) and patient"s response to ABVD chemotherapy regimen.	ABVD protocol	136-140	ATP binding cassette subfamily B member 1	Homo sapiens	41-45
21740297-9	2012	Omission of G-CSF for uncomplicated neutropenic patients receiving ABVD for Hodgkin lymphoma is cost-saving and safe.	ABVD protocol	67-71	colony stimulating factor 3	Homo sapiens	12-17
19883310-3	2009	The aim of this study was to confirm the prognostic impact of HGAL protein expression in an independent, well-characterized cohort of 232 patients with classic HL treated uniformly with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD).	ABVD protocol	239-243	germinal center associated signaling and motility	Homo sapiens	62-66
20113967-7	2010	In the ABVD group, AMH concentrations increased from the third month after the end of chemotherapy and returned to pretreatment values 12months after the end of chemotherapy.	ABVD protocol	7-11	anti-Mullerian hormone	Homo sapiens	19-22
10370786-18	1999	CONCLUSIONS: Elevation of serum IL-10 levels is frequent and is associated with inferior FFS in adults with ABVD-treated HD.	ABVD protocol	108-112	interleukin 10	Homo sapiens	32-37
12433696-0	2002	BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens.	ABVD protocol	135-139	BCL2 apoptosis regulator	Homo sapiens	0-5
12433696-10	2002	We conclude that BCL-2 is frequently expressed by HRS cells in cHD and is associated with inferior FFS in patients treated with ABVD or equivalent regimens.	ABVD protocol	128-132	BCL2 apoptosis regulator	Homo sapiens	17-22
11378548-0	2001	Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin"s lymphoma with ABVD.	ABVD protocol	115-119	colony stimulating factor 3	Homo sapiens	23-28
11378548-1	2001	UNLABELLED: The purpose of this study was to determine the effect of granulocyte colony-stimulating factor (filgrastim, G-CSF) for maintenance of chemotherapy dose-intensity in patients with stage I or II Hodgkin"s lymphoma treated with six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).	ABVD protocol	305-309	colony stimulating factor 3	Homo sapiens	69-106
11378548-8	2001	IN CONCLUSION: Secondary prophylactic G-CSF administration was necessary in more than half of patients with stage I or II Hodgkin"s lymphoma during chemotherapy with ABVD.	ABVD protocol	166-170	colony stimulating factor 3	Homo sapiens	38-43
17335133-0	2005	beta(2)-microglobulin in Hodgkin"s lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens.	ABVD protocol	94-98	beta-2-microglobulin	Homo sapiens	0-21
15370254-1	2004	Elevated pretreatment serum interleukin-10 (IL-10) is associated with inferior progression-free survival (PFS) in patients with Hodgkin"s disease (HD) treated with ABVD or equivalent regimens.	ABVD protocol	164-168	interleukin 10	Homo sapiens	28-42
15370254-1	2004	Elevated pretreatment serum interleukin-10 (IL-10) is associated with inferior progression-free survival (PFS) in patients with Hodgkin"s disease (HD) treated with ABVD or equivalent regimens.	ABVD protocol	164-168	interleukin 10	Homo sapiens	44-49
7521204-11	1994	CONCLUSION: CAV therapy was moderately effective as third-line salvage in patients with HD resistant to alternating MOPP/ABVD or previously given two different regimens for relapse; the toxicity was mostly hematological and supportive therapy was needed in one-third of the patients.	ABVD protocol	121-125	caveolin 2	Homo sapiens	12-15
9292744-1	1997	The main objective of this study was to assess to what extent filgrastim (G-CSF, Amgen-Roche) can facilitate administration of the full dose intensity of MOPP/ABVD chemotherapy to patients with Hodgkin"s disease.	ABVD protocol	159-163	colony stimulating factor 3	Homo sapiens	74-79
30290903-11	2018	For HD9 trial patients, 15-year progression-free survival was 57 0% (95% CI 50 0-64 0) for COPP/ABVD, 66 8% (61 9-71 8) for bBEACOPP, and 74 0% (69 0-79 0) for eBEACOPP, 15-year overall survival was 72 3% (95% CI 66 5-78 1), 74 5% (70 1-78 9), and 80 9% (76 7-85 0), respectively.	ABVD protocol	96-100	histone deacetylase 9	Homo sapiens	4-7
2438613-8	1987	In HD3, 58 out of 93 patients (62%) achieved complete remission after induction chemotherapy with COPP/ABVD.	ABVD protocol	103-107	histone deacetylase 3	Homo sapiens	3-6
2452393-7	1988	In HD3, 86 of 137 patients (63%) achieved complete remission after induction chemotherapy with 3 x COPP + ABVD.	ABVD protocol	106-110	histone deacetylase 3	Homo sapiens	3-6
2420444-6	1986	Thrombocytopenia was less frequently observed with ADM-Reg (30%), particularly following ABVD (13%), compared to MOPP (73%).	ABVD protocol	89-93	regenerating family member 1 alpha	Homo sapiens	55-58
26758765-0	2016	Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis.	ABVD protocol	112-116	colony stimulating factor 3	Homo sapiens	0-37
28992524-10	2017	INTERPRETATION: Early reduction of TARC serum levels can predict success of treatment, being associated with achievement of interim PET-2 negative and favorable long-term outcome in HL patients receiving ABVD as front-line therapy.	ABVD protocol	204-208	C-C motif chemokine ligand 17	Homo sapiens	35-39
28484155-0	2017	Interdigitating dendritic cell sarcoma successfully treated with ABVD therapy in which serum CEA levels correlated with disease activity.	ABVD protocol	65-69	CEA cell adhesion molecule 3	Homo sapiens	93-96
25142947-0	2014	Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy.	ABVD protocol	93-97	beta-2-microglobulin	Homo sapiens	33-53